Recombinant Mouse BMPR-IA/ALK-3 Fc Chimera Protein, CF

Catalog #: 7054-MR Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
7054-MR-100

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Mouse BMPR-IA/ALK-3 Fc Chimera Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to inhibit rhBMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. Nakamura, K. et al. (1999) Exp. Cell Res. 250:351.

The ED₅₀ for this effect is 0.03‑0.12 μg/mL in the presence of 30 ng/mL of recombinant human BMP-4.

Source

Mouse myeloma cell line, NS0-derived mouse BMPR-IA/ALK-3 protein

Mouse BMPR-1A/ALK-3 (Met1 - Arg152) Accession # NP_033888	IEGRDP	MouseIgG_2A (Glu98 - Lys330)
N-terminus		C-terminus

Accession #

NP_033888

N-terminal Sequence
Analysis

No results obtained: Gln24 predicted, N-sequencing might be blocked

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

41.3 kDa (monomer)

SDS-PAGE

57-60 kDa, reducing conditions

Product Datasheets

7054-MR

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

7054-MR

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 100 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: BMPR-IA/ALK-3

Bone Morphogenetic Protein Receptor IA (BMPR‑IA), also known as ALK‑3, BRK‑1, and CD292, is a glycosylated 60 ‑ 65 kDa type I receptor in the TGF‑ beta serine/threonine kinase receptor family (1 ‑ 3). Binding of TGF‑ beta superfamily ligands induces formation of a heterotetrameric complex that contains two chains each of a type I and a type II receptor in multiple combinations. The type II receptors phosphorylate the type I receptors which then phosphorylate and activate Smad signal transduction proteins (1, 2). Mature mouse BMPR‑IA consisits of a 129 amino acid (aa) extracellular domain (ECD), a 24 aa transmembrane segment, and a 356 aa cytoplasmic region that contains the tyrosine kinase domain (4, 5). Within the ECD, mouse BMPR‑IA shares 98% aa sequence identity with human and rat BMPR‑IA. BMPR‑IA is involved in the development and function of a wide range of tissues. During early embryogenesis it is required for migration of the anterior visceral endoderm (AVE) and proper development of the anterior‑posterior axis (6). Tissue‑specific conditional knockout experiments have demonstrated the importance of BMPR‑IA in the development and morphogenesis of the heart, lung, palate, teeth, and mandible (7 ‑ 9). In the adult, BMPR‑IA plays a role in glucose-stimulated insulin secretion by pancreatic beta cells, osteoclast activity and bone remodeling, reactive astrocyte‑mediated scar formation following spinal cord injury, and ovulation and fertility (10 ‑ 13).

References

Wu, M.Y. and C.S. Hill (2009) Dev. Cell 16:329.
Nickel, J. et al. (2009) Cytokine Growth Factor Rev. 20:367.
de Caestecker, M. (2004) Cytokine Growth Factor Rev. 15:1.
Dewulf, N. et al. (1995) Endocrinology 136:2652.
Koenig, B.B. et al. (1994) Mol. Cell. Biol. 14:5961.
Miura, S. et al. (2010) Dev. Biol. 341:246.
Gaussin, V. et al. (2002) Proc. Natl. Acad. Sci. 99:2878.
Sun, J. et al. (2008) Am. J. Pathol. 172:571.
Li, L. et al. (2011) Dev. Biol. 349:451.
Goulley, J. et al. (2007) Cell Metab. 5:207.
Kamiya, N. et al. (2008) J. Bone Miner. Res. 23:2007.
Sahni, V. et al. (2010) J. Neurosci. 30:1839.
Edson, M.A. et al. (2010) Mol. Endocrinol. 24:1251.

Long Name

Bone Morphogenetic Protein Receptor IA/Activin Receptor-like Kinase 3

Entrez Gene IDs

657 (Human); 12166 (Mouse)

Alternate Names

ACVRLK310q23del; ALK-3; ALK3EC 2.7.11.30; BMP type-1A receptor; BMPR1A; BMPR-1A; BMPRIA; BMPR-IA; bone morphogenetic protein receptor type-1A; bone morphogenetic protein receptor, type IA; CD292 antigen; CD292; EC 2.7.11; Serine/threonine-protein kinase receptor R5; SKR5; type II-like kinase 3